Form 4 for KYTX Kyverna Therapeutics, Inc.
Accepted 2025-06-02 00:00:00 ET · period of report 2025-05-29 · accession 0000950170-25-080459 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-02 | 2025-05-29 | KYTX | Shaw Christi | Dir | A - Grant | $0.00 | +16.6K | 16.6K | New | $0 |
| D | 2025-06-02 | 2025-05-29 | KYTX | Shaw Christi | Dir | A - Grant | $0.00 | +65.4K | 65.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-29 | A | A | 16,634 | $0.00 | 16,634 | D | — | — | (F1) Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
| 2 | Derivative | Stock Option (right to buy) | 2025-05-29 | A | A | 65,351 | $0.00 | 65,351 | D | $2.63 · — to 2035-05-29 | 65,351 Common Stock | (F2) All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |